Julia Vitarello with her daughter Mila, 8, who has a rare neurological disorder, at their home in Longmont, Colo., Oct. 9, 2019. (Nick Cote/The New York Times)

A new drug, created to treat just one patient, has pushed the bounds of personalized medicine and has raised unexplored regulatory and ethical questions, scientists reported Wednesday.

The drug, described in the New England Journal of Medicine, is believed to be the first “custom” treatment for a genetic disease. It is called milasen, named after the only patient who will ever take it: Mila (mee-lah) Makovec, who lives with her mother, Julia Vitarello, in Longmont, Colorado.

Mila, 8, has a rapidly progressing neurological disorder that is fatal. Her symptoms started at age 3. Within a few years, she had gone from

Read More At Article Source | Article Attribution